Halil Göksel Güzel

13PUBLICATIONS
122CO-AUTHORS
Haematological tumoursCommunication studiesPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|Jun 26, 2026
Does Social Media Use Associate with Vasomotor, Sexual, and Musculoskeletal Symptoms in Breast Cancer Survivors Receiving Endocrine Therapy?

|Apr 03, 2026
Prognostic Impact of Cetuximab-Related Hypomagnesemia and Hypokalemia in RAS/RAF Wild-Type Colorectal Cancer: A Multicenter Study.

Halil Göksel Güzel, Derya Kıvrak Salim, Ece Ulukal Karancı

|Feb 27, 2026
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

Baris Koksal, Hasan Cagri Yildirim, Deniz Can Guven

|Feb 11, 2026
Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Salih Tunbekici, Hamit Bal, Oguzcan Kınıkoglu

|Jan 28, 2026
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkish Oncology Centers.

Halil Göksel Güzel, Arif Hakan Önder, Yusuf İlhan

Pageof 3

Frequent Collaborators

5 joint publications

Banu Öztürk

3 joint publications

Derya Kıvrak Salim

3 joint publications

Elif Şahin

2 joint publications

Murad Guliyev